Company intelligence / Profile preview

ProBioGen

Ownership: Private
Employees: ~350
Development stage: Commercial

Overview

As a leading CDMO with over three decades of experience, ProBioGen provides end-to-end process development and GMP manufacturing of biologics—including proteins, monoclonal antibodies, viral vectors for vaccines/gene therapies—and offers proprietary technologies such as GlymaxX® to enhance product efficacy. The company’s clients have advanced their products into the clinic using its services.

Modalities: Monoclonal antibodyRecombinant proteinViral vector (for gene therapy and vaccines)Cell therapy products
Industry: Contract Manufacturing Organization

Partnerships

Thermo Fisher ScientificBoehringer Ingelheim

Beyond the preview

Go deeper on ProBioGen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProBioGen.

Explore the full profile